Cargando…

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate

BACKGROUND AND PURPOSE: Combretastatin A-4 3-O-phosphate (CA4P) is in clinical trial as a tumour vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear. We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the effects of this drug in vivo. EX...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, L J, Mukherjee, D, Fisher, M, Reyes-Aldasoro, C C, Akerman, S, Kanthou, C, Tozer, G M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294113/ https://www.ncbi.nlm.nih.gov/pubmed/24930520 http://dx.doi.org/10.1111/bph.12817

Ejemplares similares

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
por: Dachs, Gabi U, et al.
Publicado: (2006)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics
por: Kanthou, Chryso, et al.
Publicado: (2014)

Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
por: Beauregard, D. A., et al.
Publicado: (1998)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats
por: Nagashima, Yoshiyasu, et al.
Publicado: (2023)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
por: Bao, Xin, et al.
Publicado: (2021)

Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019)

Suppressed vascular Rho-kinase activation is a protective cardiovascular mechanism in obese female mice
por: Barbosa, Gabriela S., et al.
Publicado: (2023)

Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
por: Assali, Mohyeddin, et al.
Publicado: (2019)

Combretastatins D series and analogues: from isolation, synthetic challenges and biological activities
por: de Lima Neto, Jorge, et al.
Publicado: (2023)

Decreased vascular contractility induced by hemin is associated with a reduced rho-kinase activity
por: Awede, Bonaventure, et al.
Publicado: (2013)

RhoA/Rho-Kinase and Nitric Oxide in Vascular Reactivity in Rats with Endotoxaemia
por: Liao, Mei-Hui, et al.
Publicado: (2013)

Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues
por: do Amaral, Daniel Nascimento, et al.
Publicado: (2014)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
por: Harris, Sheila, et al.
Publicado: (2012)

Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth
por: Amaya, Clarissa N., et al.
Publicado: (2017)

Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice
por: Tang, Zhengshan, et al.
Publicado: (2020)

Tramadol regulates the activation of human platelets via Rac but not Rho/Rho-kinase
por: Iida, Hiroki, et al.
Publicado: (2023)

DLC-1:a Rho GTPase-activating protein and tumour suppressor
por: Durkin, Marian E, et al.
Publicado: (2007)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model
por: Gao, Meng, et al.
Publicado: (2016)

Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats
por: Tochinai, Ryota, et al.
Publicado: (2018)

Modelling the Tumour Microenvironment, but What Exactly Do We Mean by “Model”?
por: Reyes-Aldasoro, Constantino Carlos
Publicado: (2023)

ER stress and Rho kinase activation underlie the vasculopathy of CADASIL
por: Neves, Karla B., et al.
Publicado: (2019)

Ephrin-A5 Induces Collapse of Growth Cones by Activating Rho and Rho Kinase
por: Wahl, Siegfried, et al.
Publicado: (2000)

Blunted Activation of Rho-Kinase in Yak Pulmonary Circulation
por: Ishizaki, Takeshi, et al.
Publicado: (2015)

Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity
por: Ibrahim, Tarek S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_spmaa8o26uv712p89dt217v6dv